Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Xetra  >  Bayer    BAYN   DE000BAY0017

BAYER (BAYN)
Mes dernières consult.
Most popular
Report
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets
The feature you requested does not exist. However, we suggest the following feature:

Bayer : Studies from Bayer Update Current Data on Nerve Tissue Proteins (A tripartite mode of action approach for investigating the impact of aneugens on...

share with twitter share with LinkedIn share with facebook
share via e-mail
0
12/14/2017 | 11:40pm CET

Studies from Bayer Update Current Data on Nerve Tissue Proteins (A tripartite mode of action approach for investigating the impact of aneugens on tubulin polymerization)

By a News Reporter-Staff News Editor at Pharma Business Week -- A new study on Proteins - Nerve Tissue Proteins is now available. According to news reporting out of Berlin, Germany, by NewsRx editors, research stated, "Chemical-induced disruption of the cellular microtubule network is one key mechanism of aneugenicity. Since recent data indicate that genotoxic effects of aneugens show nonlinear dose-response relationships, margins of safety can be derived with the ultimate goal to perform a risk assessment for the support of drug development."

Our news journalists obtained a quote from the research from Bayer, "Furthermore, microtubule-interacting compounds are widely used for cancer treatment. While there is a need to support the risk assessment of tubulin-interacting chemicals using reliable mechanistic assays, no standard assays exist to date in regulatory genotoxicity testing for the distinction of aneugenic mechanisms. Recently reported methods exclusively rely on either biochemical, morphological, or cytometric endpoints. Since data requirements for the diverse fields of application of those assays differ strongly, the use of multiple assays for a correct classification of aneugens is ideal. We here report a tripartite mode of action approach comprising a cell-free biochemical polymerization assay and the cell-based methods cellular imaging and flow cytometry. The biochemical assay measures tubulin polymerization over time whereas the two cell-based assays quantify tubulin polymer mass. We herein show that the flow cytometric method yielded IC values for tubulin destabilizers and EC values for tubulin stabilizers as well as cell cycle information. In contrast, cellular imaging complemented these findings with characteristic morphological patterns. Biochemical analysis yielded kinetic information on tubulin polymerization."

According to the news editors, the research concluded: "This multiplex approach is able to create holistic effect profiles which can be individually customized to the research question with regard to quality, quantity, usability, and economy."

For more information on this research see: A tripartite mode of action approach for investigating the impact of aneugens on tubulin polymerization. Environmental and Molecular Mutagenesis, 2017;():. (Wiley-Blackwell - www.wiley.com/; Environmental and Molecular Mutagenesis - onlinelibrary.wiley.com/journal/10.1002/(ISSN)1098-2280)

Our news journalists report that additional information may be obtained by contacting V. Stock, Bayer AG, Investigational Toxicology, Muellerstraße 178, Berlin, 13353, Germany. Additional authors for this research include A. Sutter, M. Raschke and N. Queisser (see also Proteins - Nerve Tissue Proteins).

The direct object identifier (DOI) for that additional information is: https://doi.org/10.1002/em.22158. This DOI is a link to an online electronic document that is either free or for purchase, and can be your direct source for a journal article and its citation.

Keywords for this news article include: Berlin, Europe, Germany, Tubulin, Biochemicals, Biochemistry, Risk and Prevention, Microtubule Proteins, Nerve Tissue Proteins.

Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2017, NewsRx LLC

(c) 2017 NewsRx LLC, source Health Newsletters

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on BAYER
12/14 BAYER : Studies from Bayer Update Current Data on Nerve Tissue Proteins (A tripa..
12/13 BAYER : rivaroxaban submitted to U.S. FDA for approval in patients with coronary..
12/13DJPLANT IMPACT : Needs Extra GBP7 Million Funding by April, Hands up 'For Sale' Si..
12/12 Monsanto offers cash to U.S. farmers who use controversial chemical
12/08 EU regulators to warn Bayer about Monsanto bid
12/08 BAYER : Preventive Maintenance & service solution on existing Bayer/Medrad and A..
12/08 BAYER : J-- Preventive Maintenance & service solution on existing Bayer/Medrad a..
12/08 'Right steps' point to a healthier China
12/07 BAYER : Research Conducted at Bayer Has Provided New Information about Atrial Fi..
12/07 BAYER : Findings from Bayer Has Provided New Data on Liver Cancer (Exposure-resp..
More news
News from SeekingAlpha
12/15 MY JOURNEY TO FINANCIAL INDEPENDENCE : 86-Stock November Portfolio Update - Buyi..
12/15 Nektar Therapeutics down 1% premarket after Bayer bails on agreement to devel..
12/14 3 THINGS IN BIOTECH YOU SHOULD LEARN : December 14, 2017
12/11 Buy Celgene And Regeneron On The Dips As Insiders Are Buying
12/08 BLOOMBERG : Bayer to face EU objections to Monsanto deal in coming days
Financials (€)
Sales 2017 35 698 M
EBIT 2017 7 647 M
Net income 2017 6 050 M
Debt 2017 8 890 M
Yield 2017 2,50%
P/E ratio 2017 13,85
P/E ratio 2018 18,11
EV / Sales 2017 2,68x
EV / Sales 2018 2,44x
Capitalization 86 912 M
Chart BAYER
Duration : Period :
Bayer Technical Analysis Chart | BAYN | DE000BAY0017 | 4-Traders
Technical analysis trends BAYER
Short TermMid-TermLong Term
TrendsBearishBearishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 27
Average target price 121 €
Spread / Average Target 15%
EPS Revisions
Managers
NameTitle
Werner Baumann Chairman-Management Board
Werner Wenning Chairman-Supervisory Board
Johannes M. Dietsch Chief Financial Officer
Katharina Jansen Head-Science & Research
Hartmut Klusik Head-Human Resources, Technology & Sustainability
Sector and Competitors
1st jan.Capitalization (M$)
BAYER6.02%102 422
JOHNSON & JOHNSON24.03%380 546
NOVARTIS13.16%222 673
PFIZER12.81%217 327
ROCHE HOLDING LTD.3.91%211 657
MERCK AND COMPANY-4.86%152 759